Skip to main content

Horizon Therapeutics stock plunges on report FTC is preparing to block Amgen deal

The deal is bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.